A simple and rapid method to simultaneously analyze ciclesonide and its impurities in a ciclesonide metered-dose inhaler using on-line supercritical fluid extraction/supercritical fluid chromatography/quadrupole time-of-flight mass spectrometry

J Pharm Biomed Anal. 2021 Sep 10:204:114253. doi: 10.1016/j.jpba.2021.114253. Epub 2021 Jul 9.

Abstract

A simple and rapid on-line SFE/SFC/quadrupole TOF-MS method to simultaneously analyze active pharmaceutical ingredients and impurities from metered-dose inhalers (MDIs) was developed using ciclesonide MDI (CIC-MDI) as an example. CIC-MDI, as drug Alvesco®, has been approved for the treatment of bronchial asthma, and its major impurities are listed in the European Pharmacopoeia and in the supplementary package inserts of Alvesco® (called as "Pharmaceutical interview form" in Japan). In the developed method, CIC-MDI was manually sprayed only once on a glass disc prior to the SFE/SFC/quadrupole TOF-MS. In the SFE, CIC and its impurities and other impurities having various polarities and hydrophobicity, were extracted in 3.5 min and subsequently separated on a CHIRALPAK IE-3 column to be detected by quadrupole TOF-MS in 6.5 min. This method would be applicable to the analysis of other inhalable pharmaceutical products whose sample preparation requires complicated procedures, as well as to the analysis of general pharmaceutical products for profiling impurities.

Keywords: Ciclesonide metered-dose inhaler; Impurity test; In-process control; On-line SFE/SFC/quadrupole TOF-MS.

MeSH terms

  • Administration, Inhalation
  • Chromatography, Supercritical Fluid*
  • Mass Spectrometry
  • Metered Dose Inhalers
  • Pregnenediones

Substances

  • Pregnenediones
  • ciclesonide